ClinicalTrials.gg
CompletedNCT02949362Updated Mar 19, 2025Results posted

Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

A Phase 3 interventional study of Teduglutide and SOC in Short Bowel Syndrome, sponsored by Shire. Completed at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
29
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing teduglutide in Short Bowel Syndrome — 1 open to participants now, 2 under way, 1 of them phase 3. teduglutide · Short Bowel Syndrome.

Enrollment
9th of 20
29 · median 20
Started
2016
with 1 other
Phase 3
16 of 20
none open now
Registered
11th of 20
by date
Lead sponsor
13 of 20
Shire

Among the 20 studies testing teduglutide in Short Bowel Syndrome, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 16 in phase 3, and was the 11th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

1 of the 20 studies testing teduglutide in Short Bowel Syndrome is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About teduglutide

teduglutide: first FDA approval 2012 (GATTEX KIT), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing teduglutide in Short Bowel Syndrome, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of teduglutide treatment of children with short bowel syndrome (SBS) who completed the TED-C13-003 study over a long-term period. It will evaluate how these children fared after the TED-C13-003 study ended. This study will also offer teduglutide treatment to eligible subjects, regardless of treatment received in TED-C13-003.

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject provides written (subject, parent or legal guardian and, as appropriate, subject informed assent) to participate in the study before completing any study-related procedures.
  2. Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).
  3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol.

Exclusion criteria

Exclusion Criteria:

There are no exclusion criteria for this study.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    Standard of Care (SOC) Treatment +/- Teduglutide

    TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment

    Drug: Teduglutide · Other: SOC

Interventions

  • 0.05mg/kg

  • OtherSOC

    Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs) in Retrospective Observation Period

    An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. Number of participants with AEs, related AEs, serious adverse events (SAEs) and related SAEs of retrospective observation period were reported.

    Time frame: From end of the core study (TED-C13-003 [NCT01952080]) up to the beginning of the prospective period (up to Week 168)

  2. Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period

    Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age greater than or equal to \[\>=\] 2 years old) and World Health Organization (age less than \[\<\] 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)

  3. Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period

    Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Week 168 was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)

  4. Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period

    BMI Z-score was calculated by using the retrospective height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)

  5. Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Prospective Study Period

    TEAEs are defined as AEs that started or worsened on or after the first dose of teduglutide treatment in the core study. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. AESI was an TEAE or TESAE of scientific and medical concern specific to the sponsor's product or program and for which ongoing monitoring and immediate notification by the investigator to the sponsor. Number of participants With TEAEs, treatment -emergent serious adverse events (TESAEs) and adverse events of special interest (AESI) of Prospective study period were reported.

    Time frame: From the beginning of the prospective study period to End of Study (EOS) (up to Week 144)

  6. Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

    Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12

  7. Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period

    Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Cycle 6 Week 24 during the end of teduglutide treatment period of prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24

  8. Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

    BMI Z-score was calculated by using the height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12

  9. Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

    Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported. Here, mL/kg/day is abbreviated as milliliter per kilogram per day.

    Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12

  10. Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period

    Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Week 108 during the end of NTT period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Week 108

  11. Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period

    Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to cycle 6 week 24 during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24

  12. Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period

    Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to Week 120 during the end of NTT period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period) up to Week 120

  13. Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period

    Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

    Time frame: From the beginning of the prospective study period, EOS (up to Week 156)

Secondary outcomes

  1. Number of Participants Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Number of participants achieved at least 20% reduction in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.

    Time frame: At Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  2. Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Change from baseline in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  3. Percent Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Percent change from baseline in PS volume at 12 weeks interval up to Week 156 of retrospective observation period was reported.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  4. Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  5. Percent Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Percent change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  6. Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156

  7. Percent Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study. Hence, percent change was not assessed in this study.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156

  8. Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  9. Percent Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

    Percent change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.

    Time frame: Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156

  10. Number of Participants Who Achieved At Least 20, 50 and 75% Reduction in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Number of participants who achieved at least 20, 50 and 75% reduction in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: At EOT of each Cycles 1 to 6 (up to Week 140) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 20 weeks)

  11. Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  12. Percent Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Percent change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  13. Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  14. Percent Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Percent change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  15. Number of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: At EOT of each Cycles 1 to 6 (up to Week 144) (length of each Cycle 1 to 6 = 24 weeks)

  16. Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  17. Percent Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Percent change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  18. Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

  19. Percent Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

    Percent change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

    Time frame: Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)

Other outcomes

  1. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

    PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6

  2. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at End of Last NTT Period During the NTT Periods in Prospective Study Period

    PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)

  3. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

    PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6

  4. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at End of Last NTT Period During the NTT Periods in Prospective Study Period

    PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of to the end the prospective study period), End of Last NTT period (up to Week 120)

  5. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

    PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6

  6. Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at End of Last NTT Period During the NTT Periods in Prospective Study Period

    PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

    Time frame: Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)

07

Results

Posted Jun 14, 2021

Participant flow

Participants who completed TED-C13-003 (NCT01952080) were enrolled in this study which was conducted at 11 sites in the United States and United Kingdom between 09 December 2016 (first participant first visit) and 14 July 2020 (last participant last visit).

Retrospective Period
Participant flow — Retrospective Period
MilestoneRetrospective TED/NTT GroupRetrospective TED/TED GroupProspective TED/NTT GroupProspective TED/TED Group
Started24500
Completed20400
Not completed4100
Withdrew: Inform consent not signed by participant4100
Prospective Period
Participant flow — Prospective Period
MilestoneRetrospective TED/NTT GroupRetrospective TED/TED GroupProspective TED/NTT GroupProspective TED/TED Group
Started00519
Completed00415
Not completed0014
Withdrew: Discontinued the study early but didn't complete an et visit.0010
Withdrew: Other0004

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs) in Retrospective Observation Period

An AE was any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. Number of participants with AEs, related AEs, serious adverse events (SAEs) and related SAEs of retrospective observation period were reported.

Time frame:
From end of the core study (TED-C13-003 [NCT01952080]) up to the beginning of the prospective period (up to Week 168)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) in Retrospective Observation Period
ParticipantsRetrospective TED/NTT GroupRetrospective TED/TED Group
Participants with AEs234
Participants with Related AEs234
Participants with SAEs234
Participants with Related SAE00
PrimaryChange From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period

Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age greater than or equal to \[\>=\] 2 years old) and World Health Organization (age less than \[\<\] 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Reported as:
Mean · Z-score
Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period
Z-scoreRetrospective TED/NTT Group
Change From Baseline in Height for Age Z-score up to Week 168 of Retrospective Observation Period0.128 ± 0.0505
PrimaryChange From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period

Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Week 168 was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Reported as:
Mean · Z-score
Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period
Z-scoreRetrospective TED/NTT Group
Change From Baseline in Body Weight for Age Z-score up to Week 168 of Retrospective Observation Period-0.181 ± 0.0601
PrimaryChange From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period

BMI Z-score was calculated by using the retrospective height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Week 168 of retrospective observation period was reported. Data for this outcome was not planned to be collected and analyzed in retrospective TED/TED group.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to the beginning of the prospective period (up to Week 168)
Reported as:
Mean · Z-score
Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period
Z-scoreRetrospective TED/NTT Group
Change From Baseline in Body Mass Index (BMI) for Age Z-score up to Week 168 of Retrospective Observation Period-0.283 ± 0.0646
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) of Prospective Study Period

TEAEs are defined as AEs that started or worsened on or after the first dose of teduglutide treatment in the core study. A SAE was any untoward medical occurrence (whether considered to be related to investigational product or not) that at any dose: results in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, was a congenital abnormality/birth defect, was an important medical event. AESI was an TEAE or TESAE of scientific and medical concern specific to the sponsor's product or program and for which ongoing monitoring and immediate notification by the investigator to the sponsor. Number of participants With TEAEs, treatment -emergent serious adverse events (TESAEs) and adverse events of special interest (AESI) of Prospective study period were reported.

Time frame:
From the beginning of the prospective study period to End of Study (EOS) (up to Week 144)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) of Prospective Study Period
ParticipantsProspective TED/NTT GroupProspective TED/TED Group
Participants with TEAEs419
Participants with TESAEs317
Participants with AESI00
PrimaryChange From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

Height was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in height for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Reported as:
Mean · Z-score
Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
Z-scoreProspective TED/TED Group
Change From Baseline in Height for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period0.05 ± 1.068
PrimaryChange From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period

Body weight was measured using age Z-score. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in body weight for age Z-score up to Cycle 6 Week 24 during the end of teduglutide treatment period of prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24
Reported as:
Mean · Z-score
Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period
Z-scoreProspective TED/TED Group
Change From Baseline in Body Weight for Age Z-score up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period-0.66 ± NA
PrimaryChange From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

BMI Z-score was calculated by using the height and weight data. Z-score was calculated as (observed value - median value of the reference population) / standard deviation value of reference population. Centers for Disease Control and Prevention (age \>= 2 years old) and World Health Organization (age \< 2 years old) Z-score calculation charts are used for calculation. A negative Z-score indicates values lower than the mean while a positive Z-score indicates values higher than the mean. Change from baseline in BMI for age Z-score up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Reported as:
Mean · Z-score
Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
Z-scoreProspective TED/TED Group
Change From Baseline in BMI for Age Z-score up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period-0.68 ± 0.349
PrimaryAverage Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period

Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Cycle 6 Week 12 during the end of teduglutide treatment period of prospective study period was reported. Here, mL/kg/day is abbreviated as milliliter per kilogram per day.

Time frame:
Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 12
Reported as:
Mean · mL/kg/day
Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period
mL/kg/dayProspective TED/TED Group
Average Total 48-Hour Urine Output up to Cycle 6 Week 12 During the End of Teduglutide Treatment Period of Prospective Study Period14.38 ± 12.712
PrimaryAverage Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period

Average total urine output was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average total 48-Hour urine output up to Week 108 during the end of NTT period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Week 108
Reported as:
Mean · mL/kg/day
Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period
mL/kg/dayProspective TED/NTT Group
Average Total 48-Hour Urine Output up to Week 108 During the End of Non-Teduglutide Treatment (NTT) Period of Prospective Study Period22.86 ± 9.956
PrimaryAverage Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period

Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to cycle 6 week 24 during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Cycle 6 Week 24
Reported as:
Mean · Stools per day
Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period
Stools per dayProspective TED/TED Group
Average Number of Stools Per Day up to Cycle 6 Week 24 During the End of Teduglutide Treatment Period of Prospective Study Period5.50 ± NA
PrimaryAverage Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period

Average number of stools per day was calculated based on the daily data recorded in participants diaries over a 48-hour period of nutritional stability prior to each scheduled visit. Average number of stools per day up to Week 120 during the end of NTT period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period) up to Week 120
Reported as:
Mean · Stools per day
Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period
Stools per dayProspective TED/NTT Group
Average Number of Stools Per Day up to Week 120 During the End of NTT Period of Prospective Study Period3.75 ± 3.182
PrimaryNumber of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period

Number of participants with positive specific antibodies to teduglutide were used to summarize the presence of antibodies.

Time frame:
From the beginning of the prospective study period, EOS (up to Week 156)
Reported as:
Count of participants · Participants
Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period
ParticipantsProspective TED/TED Group
Number of Participants With Positive Specific Antibodies at EOS During the End of Teduglutide Treatment Period of Prospective Study Period1
SecondaryNumber of Participants Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Number of participants achieved at least 20% reduction in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.

Time frame:
At Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Count of participants · Participants
Number of Participants Achieved At Least 20 Percent (%) Reduction in Parenteral Support (PS) Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
ParticipantsRetrospective TED/NTT GroupRetrospective TED/TED Group
At Week 12122
At Week 2492
At Week 3694
At Week 4894
At Week 6094
At Week 7262
At Week 8472
At Week 96105
At Week 10895
At Week 120104
At Week 13274
At Week 14431
At Week 15601
SecondaryChange From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Change from baseline in PS volume at 12 weeks interval up to Week 156 in retrospective observation period was reported.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · mL/kg/day
Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
mL/kg/dayRetrospective TED/NTT GroupRetrospective TED/TED Group
Change at Week 12-14.45 ± 17.770-12.84 ± 17.694
Change at Week 24-9.27 ± 21.642-13.49 ± 14.530
Change at Week 36-10.65 ± 20.877-17.91 ± 17.069
Change at Week 48-12.24 ± 29.646-26.12 ± 8.044
Change at Week 60-13.85 ± 30.219-21.35 ± 12.285
Change at Week 72-13.65 ± 30.577-11.41 ± 22.030
Change at Week 84-8.74 ± 36.078-15.65 ± 19.603
Change at Week 96-12.87 ± 37.996-27.34 ± 16.531
Change at Week 108-10.35 ± 29.370-31.83 ± 14.872
Change at Week 120-12.21 ± 27.480-30.48 ± 19.043
Change at Week 132-19.20 ± 26.171-37.70 ± 12.296
Change at Week 144-16.79 ± 29.620-34.32 ± NA
Change at Week 156-7.46 ± 1.931-34.43 ± NA
SecondaryPercent Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Percent change from baseline in PS volume at 12 weeks interval up to Week 156 of retrospective observation period was reported.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · Percent change
Percent Change From Baseline in PS Volume at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent changeRetrospective TED/NTT GroupRetrospective TED/TED Group
Percent change at Week 12-24.50 ± 27.853-24.88 ± 35.649
Percent change at Week 24-10.72 ± 33.081-32.10 ± 31.645
Percent change at Week 36-13.21 ± 34.172-43.09 ± 42.753
Percent change at Week 48-14.04 ± 39.390-65.18 ± 31.650
Percent change at Week 60-16.15 ± 39.491-53.61 ± 37.141
Percent change at Week 72-14.19 ± 40.558-14.11 ± 58.452
Percent change at Week 84-8.67 ± 47.108-30.25 ± 39.598
Percent change at Week 96-12.04 ± 51.631-61.19 ± 29.335
Percent change at Week 108-10.62 ± 48.820-73.43 ± 29.298
Percent change at Week 120-12.89 ± 49.366-69.61 ± 39.194
Percent change at Week 132-20.24 ± 47.431-85.92 ± 17.457
Percent change at Week 144-7.70 ± 44.170-65.20 ± NA
Percent change at Week 156-17.21 ± 3.164-65.42 ± NA
SecondaryChange From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported. Here, kilo-calories per kilogram per day was abbreviated as (kcal/kg/day).

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · kcal/kg/day
Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
kcal/kg/dayRetrospective TED/NTT GroupRetrospective TED/TED Group
Change at Week 12-10.15 ± 13.026-2.64 ± 18.739
Change at Week 24-3.96 ± 16.970-7.25 ± 11.916
Change at Week 36-8.38 ± 17.148-6.42 ± 24.547
Change at Week 48-9.84 ± 22.144-18.11 ± 7.896
Change at Week 60-10.55 ± 23.136-10.53 ± 18.538
Change at Week 72-12.64 ± 23.642-0.05 ± 23.552
Change at Week 84-9.70 ± 24.860-5.24 ± 23.064
Change at Week 96-10.08 ± 23.998-15.09 ± 18.604
Change at Week 108-7.20 ± 22.875-19.05 ± 18.229
Change at Week 120-7.98 ± 21.425-17.18 ± 23.169
Change at Week 132-12.93 ± 18.744-27.59 ± 5.114
Change at Week 144-11.97 ± 17.977-25.53 ± NA
Change at Week 156-6.55 ± 4.708-25.67 ± NA
SecondaryPercent Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Percent change from baseline in PS caloric intake at 12 weeks interval up to Week 156 of retrospective observation period was reported.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · Percent change
Percent Change From Baseline in PS Caloric Intake at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent changeRetrospective TED/NTT GroupRetrospective TED/TED Group
Percent change at Week 12-24.91 ± 29.0017.64 ± 82.061
Percent change at Week 24-10.12 ± 42.431-21.29 ± 37.759
Percent change at Week 36-18.29 ± 41.070-3.38 ± 118.167
Percent change at Week 48-21.03 ± 43.924-59.31 ± 38.042
Percent change at Week 60-20.63 ± 44.903-25.65 ± 83.470
Percent change at Week 72-25.48 ± 45.03523.26 ± 99.380
Percent change at Week 84-20.42 ± 45.2874.41 ± 102.162
Percent change at Week 96-21.12 ± 46.005-36.49 ± 72.357
Percent change at Week 108-16.41 ± 46.034-50.24 ± 70.513
Percent change at Week 120-18.79 ± 45.774-38.58 ± 97.750
Percent change at Week 132-29.37 ± 40.170-82.01 ± 21.165
Percent change at Week 144-25.25 ± 33.618-60.36 ± NA
Percent change at Week 156-15.66 ± 7.700-60.69 ± NA
SecondaryChange From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156

No measurements were reported for this outcome.

SecondaryPercent Change From Baseline in Number of Hours Per Day of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Data for this outcome measure was not analyzed and collected because changes from baseline for prescribed hours per day were not collected at baseline in the core study. Hence, percent change was not assessed in this study.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]) up to Week 156

No measurements were reported for this outcome.

SecondaryChange From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · Days per week
Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Days per weekRetrospective TED/NTT GroupRetrospective TED/TED Group
Change at Week 12-0.38 ± 1.469-1.20 ± 2.683
Change at Week 24-0.29 ± 1.429-1.00 ± 2.000
Change at Week 36-0.43 ± 1.562-2.60 ± 2.793
Change at Week 48-0.61 ± 2.017-4.50 ± 2.082
Change at Week 60-0.61 ± 2.017-3.00 ± 3.536
Change at Week 72-0.64 ± 2.060-1.40 ± 2.966
Change at Week 84-0.64 ± 2.060-1.40 ± 2.966
Change at Week 96-1.17 ± 2.665-2.00 ± 3.536
Change at Week 108-0.88 ± 2.365-3.80 ± 3.701
Change at Week 120-0.95 ± 2.459-3.80 ± 3.701
Change at Week 132-1.00 ± 2.542-5.25 ± 2.062
Change at Week 1440.00 ± 0.000-3.00 ± NA
Change at Week 1560.00 ± 0.000-3.00 ± NA
SecondaryPercent Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period

Percent change from baseline in number of days per Week of PS usage at 12 weeks interval up to Week 156 in retrospective observation period was reported.

Time frame:
Baseline (Baseline visit in the core study [TED-C13-003 (NCT01952080)]), Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108, 120, 132, 144, and 156
Reported as:
Mean · Percent change
Percent Change From Baseline in Number of Days Per Week of PS Usage at 12 Weeks Interval up to Week 156 of Retrospective Observation Period
Percent changeRetrospective TED/NTT GroupRetrospective TED/TED Group
Percent change at Week 12-6.25 ± 22.421-14.86 ± 41.913
Percent change at Week 24-4.17 ± 20.412-14.29 ± 28.571
Percent change at Week 36-6.21 ± 22.309-34.86 ± 44.648
Percent change at Week 48-8.70 ± 28.810-64.29 ± 29.738
Percent change at Week 60-8.70 ± 28.810-40.57 ± 54.638
Percent change at Week 72-9.09 ± 29.424-17.71 ± 45.821
Percent change at Week 84-9.09 ± 29.424-17.71 ± 45.821
Percent change at Week 96-16.67 ± 38.069-26.29 ± 53.886
Percent change at Week 108-12.50 ± 33.783-52.00 ± 57.407
Percent change at Week 120-13.64 ± 35.125-52.00 ± 57.407
Percent change at Week 132-14.29 ± 36.314-75.00 ± 29.451
Percent change at Week 1440.00 ± 0.000-42.86 ± NA
Percent change at Week 1560.00 ± 0.000-42.86 ± NA
SecondaryNumber of Participants Who Achieved At Least 20, 50 and 75% Reduction in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Number of participants who achieved at least 20, 50 and 75% reduction in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
At EOT of each Cycles 1 to 6 (up to Week 140) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 20 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved At Least 20, 50 and 75% Reduction in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
ParticipantsProspective TED/TED Group
Cycle 1: EOT at >= 20%13
Cycle 2: EOT at >= 20%12
Cycle 3: EOT at >= 20%10
Cycle 4: EOT at >= 20%9
Cycle 5: EOT at >= 20%7
Cycle 6: EOT at >= 20%5
Cycle 1: EOT at >= 50%5
Cycle 2: EOT at >= 50%10
Cycle 3: EOT at >= 50%9
Cycle 4: EOT at >= 50%9
Cycle 5: EOT at >= 50%5
Cycle 6: EOT at >= 50%4
Cycle 1: EOT at >= 75%2
Cycle 2: EOT at >= 75%4
Cycle 3: EOT at >= 75%6
Cycle 4: EOT at >= 75%5
Cycle 5: EOT at >= 75%4
Cycle 6: EOT at >= 75%3
SecondaryChange From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · mL/kg/day
Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
mL/kg/dayProspective TED/TED Group
Change at Cycle 1: EOT-25.18 ± 19.915
Change at Cycle 2: EOT-28.59 ± 29.856
Change at Cycle 3: EOT-40.05 ± 29.711
Change at Cycle 4: EOT-40.10 ± 30.359
Change at Cycle 5: EOT-40.49 ± 24.259
Change at Cycle 6: EOT-47.57 ± 26.243
SecondaryPercent Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Percent change from baseline in PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent changeProspective TED/TED Group
Percent change: Cycle 1: EOT-38.02 ± 28.611
Percent change: Cycle 2: EOT-45.58 ± 48.150
Percent change: Cycle 3: EOT-62.16 ± 41.805
Percent change: Cycle 4: EOT-62.92 ± 38.466
Percent change: Cycle 5: EOT-73.49 ± 34.593
Percent change: Cycle 6: EOT-78.75 ± 33.949
SecondaryChange From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · kcal/kg/day
Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
kcal/kg/dayProspective TED/TED Group
Change at Cycle 1: EOT-17.66 ± 17.649
Change at Cycle 2: EOT-19.95 ± 23.402
Change at Cycle 3: EOT-27.66 ± 19.668
Change at Cycle 4: EOT-24.05 ± 22.746
Change at Cycle 5: EOT-26.98 ± 27.465
Change at Cycle 6: EOT-27.53 ± 32.486
SecondaryPercent Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Percent change from baseline in PS caloric intake at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in PS Caloric Intake at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent changeProspective TED/TED Group
Percent change at Cycle 1: EOT-33.50 ± 40.439
Percent change at Cycle 2: EOT-42.06 ± 44.077
Percent change at Cycle 3: EOT-62.47 ± 37.677
Percent change at Cycle 4: EOT-49.51 ± 54.041
Percent change at Cycle 5: EOT-54.08 ± 64.002
Percent change at Cycle 6: EOT-59.00 ± 57.267
SecondaryNumber of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Number of participants who achieved at least 100% reduction in complete weaning of PS volume at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
At EOT of each Cycles 1 to 6 (up to Week 144) (length of each Cycle 1 to 6 = 24 weeks)
Reported as:
Count of participants · Participants
Number of Participants Who Achieved 100% Reduction in Complete Weaning of PS Volume at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
ParticipantsProspective TED/TED Group
Cycle 1: EOT1
Cycle 2: EOT3
Cycle 3: EOT6
Cycle 4: EOT5
Cycle 5: EOT4
Cycle 6: EOT3
SecondaryChange From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Hours per day
Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Hours per dayProspective TED/TED Group
Change at Cycle 1: EOT-3.40 ± 3.752
Change at Cycle 2: EOT-4.80 ± 5.360
Change at Cycle 3: EOT-6.69 ± 4.247
Change at Cycle 4: EOT-6.48 ± 4.881
Change at Cycle 5: EOT-6.71 ± 6.175
Change at Cycle 6: EOT-8.08 ± 6.075
SecondaryPercent Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Percent change from baseline in number of hours per day of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Number of Hours Per Day of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent changeProspective TED/TED Group
Percent change at Cycle 1: EOT-26.32 ± 29.732
Percent change at Cycle 2: EOT-40.47 ± 40.476
Percent change at Cycle 3: EOT-57.61 ± 36.973
Percent change at Cycle 4: EOT-55.87 ± 42.693
Percent change at Cycle 5: EOT-58.85 ± 52.717
Percent change at Cycle 6: EOT-66.39 ± 46.042
SecondaryChange From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Days per week
Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Days per weekProspective TED/TED Group
Change at Cycle 1: EOT-0.60 ± 1.892
Change at Cycle 2: EOT-1.93 ± 2.840
Change at Cycle 3: EOT-3.03 ± 3.257
Change at Cycle 4: EOT-2.99 ± 3.610
Change at Cycle 5: EOT-3.83 ± 3.969
Change at Cycle 6: EOT-4.37 ± 3.618
SecondaryPercent Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period

Percent change from baseline in number of days per week of PS usage at EOT of each cycle during the end of teduglutide treatment period in prospective study period was reported.

Time frame:
Baseline (from the beginning of the prospective study period), EOT of each Cycles 1 to 6 (up to Week 136) (length of each Cycle 1 to 5 = 24 weeks, length of Cycle 6 = 16 weeks)
Reported as:
Mean · Percent change
Percent Change From Baseline in Number of Days Per Week of PS Usage at EOT of Each Cycle During the End of Teduglutide Treatment Period of Prospective Study Period
Percent changeProspective TED/TED Group
Percent change at Cycle 1: EOT-9.01 ± 27.472
Percent change at Cycle 2: EOT-29.24 ± 40.525
Percent change at Cycle 3: EOT-44.51 ± 47.929
Percent change at Cycle 4: EOT-42.38 ± 51.929
Percent change at Cycle 5: EOT-54.29 ± 57.404
Percent change at Cycle 6: EOT-62.86 ± 51.110
Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Reported as:
Mean · Score on a scale
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
Score on a scaleProspective TED/TED Group
Physical Functioning: Change at Cycle 1 Week 12-0.39 ± 24.326
Physical Functioning: Change at Cycle 1 Week 24-0.83 ± 10.726
Physical Functioning: Change at Cycle 2 Week 122.34 ± 15.717
Physical Functioning: Change at Cycle 2 Week 242.40 ± 16.296
Physical Functioning: Change at Cycle 3 Week 12-0.57 ± 16.167
Physical Functioning: Change at Cycle 3 Week 24-1.74 ± 25.963
Physical Functioning: Change at Cycle 4 Week 12-1.74 ± 22.378
Physical Functioning: Change at Cycle 4 Week 241.79 ± 19.998
Physical Functioning: Change at Cycle 5 Week 12-7.50 ± 19.961
Physical Functioning: Change at Cycle 5 Week 24-2.34 ± 14.292
Physical Functioning: Change at Cycle 6 Week 12-6.25 ± 22.244
Physical Functioning: Change at Cycle 6 Week 243.13 ± NA
Emotional Functioning: Change at Cycle 1 Week 124.17 ± 18.843
Emotional Functioning: Change at Cycle 1 Week 24-4.67 ± 24.511
Emotional Functioning: Change at Cycle 2 Week 12-3.33 ± 28.591
Emotional Functioning: Change at Cycle 2 Week 24-0.38 ± 21.454
Emotional Functioning: Change at Cycle 3 Week 127.05 ± 29.661
Emotional Functioning: Change at Cycle 3 Week 24-8.33 ± 36.120
Emotional Functioning: Change at Cycle 4 Week 122.78 ± 33.481
Emotional Functioning: Change at Cycle 4 Week 24-0.71 ± 35.786
Emotional Functioning: Change at Cycle 5 Week 12-11.00 ± 40.566
Emotional Functioning: Cycle 5 Week 24-17.50 ± 37.804
Emotional Functioning: Change at Cycle 6 Week 12-5.63 ± 56.065
Emotional Functioning: Change at Cycle 6 Week 2417.50 ± NA
Social Functioning: Change at Cycle 1 Week 12-15.00 ± NA
Social Functioning: Change at Cycle 1 Week 24-10.00 ± NA
Social Functioning: Change at Cycle 2 Week 12-5.00 ± NA
Social Functioning: Change at Cycle 2 Week 240.00 ± NA
Social Functioning: Change at Cycle 3 Week 1210.00 ± NA
Social Functioning: Change at Cycle 3 Week 240.00 ± NA
Social Functioning: Change at Cycle 4 Week 1210.00 ± NA
Social Functioning: Change at Cycle 4 Week 2410.00 ± NA
Social Functioning: Change at Cycle 5 Week 1210.00 ± NA
Social Functioning: Change at Cycle 5 Week 2410.00 ± NA
Social Functioning: Change at Cycle 6 Week 1210.00 ± NA
School Functioning: Change at Cycle 1 Week 125.67 ± 19.445
School Functioning: Change at Cycle 1 Week 242.00 ± 20.160
School Functioning: Change at Cycle 2 Week 12-5.00 ± 24.027
School Functioning: Change at Cycle 2 Week 248.75 ± 16.394
School Functioning: Change at Cycle 3 Week 123.64 ± 23.355
School Functioning: Change at Cycle 3 Week 24-3.33 ± 22.500
School Functioning: Change at Cycle 4 Week 120.00 ± 15.000
School Functioning: Change at Cycle 4 Week 2413.57 ± 8.018
School Functioning: Change at Cycle 5 Week 1215.00 ± 11.180
School Functioning: Change at Cycle 5 Week 2418.75 ± 8.539
School Functioning: Change at Cycle 6 Week 1213.75 ± 4.787
School Functioning: Change at Cycle 6 Week 2420.00 ± NA
Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Generic Core Scale (GCS) Score at End of Last NTT Period During the NTT Periods in Prospective Study Period

PedsQL GCS was used for quality of life assessment. It encompasses 4 dimensions of functioning (physical, emotional, social, school). Age groups are: Toddler (2-4 years), Young child (5-7 years), Child (8-12 years), and Teens (13-18 years). Depending on the participants age, the questionnaire may be completed by either the participant or the parent/caregiver as appropriate. For the Toddler group, the PedsQL GCS consisted of 21 items, using a 5-point Likert scale (0 to 4); for all other groups, the PedsQL GCS consisted of 23 items, with a 3-point Likert scale (0, 2, 4) for the young child, and a 5-point Likert scale for the child and teens groups. Scores are transformed on a scale from 0 to 100 where 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Reported as:
Mean · Score on a scale
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
Score on a scaleProspective TED/TED Group
Change at Cycle 1 Week 121.39 ± 15.742
Change at Cycle 1 Week 241.56 ± 13.372
Change at Cycle 2 Week 120.10 ± 13.622
Change at Cycle 2 Week 241.90 ± 11.664
Change at Cycle 3 Week 122.72 ± 15.051
Change at Cycle 3 Week 243.90 ± 16.018
Change at Cycle 4 Week 122.14 ± 20.762
Change at Cycle 4 Week 244.66 ± 23.546
Change at Cycle 5 Week 120.11 ± 14.105
Change at Cycle 5 Week 242.23 ± 16.099
Change at Cycle 6 Week 125.13 ± 18.084
Change at Cycle 6 Week 24-17.86 ± NA
Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Family Impact Module Total Score at End of Last NTT Period During the NTT Periods in Prospective Study Period

PedsQL Family Impact Module was composed of 36 items comprising Physical Functioning (6 items), Emotional Functioning (5 items), Social Functioning (4 items), Cognitive Functioning (5 items), Communication (3 items), Worry (5 items), Daily Activities (3 items) and Family Relationships (5 items). Total score was calculated as the sum of all the items over the number of items answered on all the scales. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of to the end the prospective study period), End of Last NTT period (up to Week 120)

No measurements were reported for this outcome.

Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period

PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of the prospective study period), Week 12 and 24 of Cycles 1 to 6
Reported as:
Mean · Score on a scale
Change From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at Week 12 and 24 of Each Treatment Cycle During the Teduglutide Treatment Periods of Prospective Study Period
Score on a scaleProspective TED/TED Group
Food and Drink Limits: Change at Cycle 1 Week 12-2.08 ± 30.460
Food and Drink Limits: Change at Cycle 1 Week 24-7.06 ± 27.524
Food and Drink Limits: Change at Cycle 2 Week 12-0.83 ± 29.723
Food and Drink Limits: Change at Cycle 2 Week 249.31 ± 26.292
Food and Drink Limits: Change at Cycle 3 Week 121.19 ± 35.784
Food and Drink Limits: Change at Cycle 3 Week 24-0.08 ± 29.511
Food and Drink Limits: Change at Cycle 4 Week 12-4.63 ± 33.750
Food and Drink Limits: Change at Cycle 4 Week 241.04 ± 35.895
Food and Drink Limits: Change at Cycle 5 Week 121.19 ± 21.343
Food and Drink Limits: Change at Cycle 5 Week 24-17.36 ± 44.986
Food and Drink Limits: Change at Cycle 6 Week 12-1.39 ± 30.142
Food and Drink Limits: Change at Cycle 6 Week 24-45.83 ± NA
Diarrhea: Change at Cycle 1 Week 127.79 ± 23.137
Diarrhea: Change at Cycle 1 Week 249.33 ± 23.279
Diarrhea: Change at Cycle 2 Week 125.48 ± 15.144
Diarrhea: Change at Cycle 2 Week 246.72 ± 19.880
Diarrhea: Change at Cycle 3 Week 1213.27 ± 22.124
Diarrhea: Change at Cycle 3 Week 245.19 ± 21.569
Diarrhea: Change at Cycle 4 Week 129.13 ± 18.653
Diarrhea: Change at Cycle 4 Week 2412.95 ± 26.448
Diarrhea: Change at Cycle 5 Week 1210.71 ± 23.237
Diarrhea: Change at Cycle 5 Week 248.33 ± 30.612
Diarrhea: Change at Cycle 6 Week 125.95 ± 22.961
Diarrhea: Change at Cycle 6 Week 24-7.14 ± NA
Other pre-specifiedChange From Baseline In Pediatric Quality of Life Inventory (PedsQL) Gastrointestinal Symptoms Module at End of Last NTT Period During the NTT Periods in Prospective Study Period

PedsQL GI symptoms module was composed of 58 items, comprised of 10 different symptom scales that assess gastrointestinal symptom-related quality of life: food and drink limits, trouble swallowing, heartburn and reflux, nausea and vomiting, gas and bloating, constipation, blood in poop, and diarrhea. Only the scales of food and drink limits (6 items) and diarrhea (7 items) was used in this study. Subscale score was calculated as the sum of the items over the number of items answered in the scale. Scores are transformed on a scale from 0 to 100 were 0=100, 1=75, 2=50, 3=25, and 4=0. Higher scores indicate improved quality of life.

Time frame:
Baseline (from the beginning of the prospective study period), End of Last NTT period (up to Week 120)

No measurements were reported for this outcome.

Adverse events

Collected over From start of screening up to end of the study (up to 168 weeks). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Retrospective TED/NTT Group0/24 (0%)23/24 (95.8%)1/24 (4.2%)
Retrospective TED/TED Group0/5 (0%)4/5 (80%)1/5 (20%)
Prospective TED/NTT Group0/5 (0%)3/5 (60%)4/5 (80%)
Prospective TED/TED Group0/19 (0%)17/19 (89.5%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 86
Most frequent serious events
EventRetrospective TED/NTT GroupRetrospective TED/TED GroupProspective TED/NTT GroupProspective TED/TED Group
Device related infectionInfections and infestations17/242/51/59/19
PyrexiaGeneral disorders14/243/50/57/19
Device breakageProduct Issues6/241/50/50/19
InfluenzaInfections and infestations5/240/50/54/19
Device malfunctionProduct Issues5/241/50/50/19
Abdominal adhesionsGastrointestinal disorders0/240/51/50/19
IleusGastrointestinal disorders1/241/50/52/19
Intestinal obstructionGastrointestinal disorders0/240/51/50/19
CellulitisInfections and infestations0/240/51/51/19
CystitisInfections and infestations0/240/51/50/19
Most frequent other events
Showing 10 of 145
Most frequent other events
EventRetrospective TED/NTT GroupRetrospective TED/TED GroupProspective TED/NTT GroupProspective TED/TED Group
Upper respiratory tract infectionInfections and infestations0/240/53/57/19
VomitingGastrointestinal disorders0/240/52/510/19
Abdominal painGastrointestinal disorders0/241/52/57/19
Viral upper respiratory tract infectionInfections and infestations0/240/52/50/19
CoughRespiratory, thoracic and mediastinal disorders0/240/50/56/19
DiarrhoeaGastrointestinal disorders0/240/50/55/19
C-reactive protein increasedInvestigations0/240/50/55/19
HeadacheNervous system disorders0/240/51/55/19
RashSkin and subcutaneous tissue disorders0/240/51/54/19
AnaemiaBlood and lymphatic system disorders0/240/51/53/19

Baseline characteristics

Safety population included all enrolled participants who provided informed consent for the prospective portion and met all the inclusion criteria.

Age, Continuous
Age, Continuous(Years)Retrospective TED/NTT GroupRetrospective TED/TED GroupTotal
Mean4.0 ± 2.888.2 ± 5.504.7 ± 3.71
Sex: Female, Male
Sex: Female, Male(Participants)Retrospective TED/NTT GroupRetrospective TED/TED GroupTotal
Female909
Male15520
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Retrospective TED/NTT GroupRetrospective TED/TED GroupTotal
Ethnicity — Hispanic or Latino9110
Ethnicity — Not Hispanic or Latino15318
Ethnicity — Not allowed based on local regulations011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Retrospective TED/NTT GroupRetrospective TED/TED GroupTotal
Race — White20323
Race — Black or African American213
Race — Asian011
Race — Other202
08

Study locations

11 sites
  • Childrens Hospital Los Angeles - RHU
    Los Angeles, California 90027, United States
  • Mattel Children's Hospital UCLA
    Los Angeles, California 90095, United States
  • Riley Hospital for Children
    Indianapolis, Indiana 46202, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Mercy Hospitals and Clinics
    Kansas City, Missouri 64108, United States
  • Children's Hospital at Montefiore
    Bronx, New York 10467, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Texas Children's Hospital
    Houston, Texas 77030, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin School of Medicine and Public Health
    Madison, Wisconsin 53792, United States
  • Great Ormond Children's Hospital
    London, WC1N 3JH, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — De-identified individual participant data from this particular study will not be shared as the data are subject to contractual (or consent) provisions that prohibit transfer to third parties.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Jul 2020, 43 months.

Results were first posted in Jun 2021, 11 months after primary completion.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 43 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 5, 2016
First posted
Oct 31, 2016
StartActual
Dec 9, 2016
Primary completionActual
Jul 14, 2020
CompletionActual
Jul 14, 2020
Results first posted
Jun 14, 2021
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02949362
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Oct 31, 2016
Start date
Dec 9, 2016
Primary completion
Jul 14, 2020
Completion
Jul 14, 2020
Results posted
Jun 14, 2021
Last update
Mar 19, 2025

Study contacts

Shire Study Physician
principal investigator · Shire

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Teduglutide

Start the discussion